Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Stock Rated “Moderate Buy” by Wall Street Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $3.17.

Several research analysts have recently weighed in on INO shares. Piper Sandler reaffirmed an “overweight” rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Zacks Research cut shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 12th. Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and boosted their price target for the stock from $1.80 to $3.00 in a report on Thursday, August 13th. Weiss Ratings lowered shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. Finally, HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Thursday, August 13th.

Institutional Trading of Inovio Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Prime Capital Investment Advisors LLC raised its position in shares of Inovio Pharmaceuticals by 312.4% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 53,510 shares during the last quarter. LexAurum Advisors LLC purchased a new position in Inovio Pharmaceuticals in the 3rd quarter valued at about $118,000. Green Alpha Advisors LLC lifted its stake in Inovio Pharmaceuticals by 68.8% in the 3rd quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 46,802 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in Inovio Pharmaceuticals in the 2nd quarter worth about $37,000. Finally, Squarepoint Ops LLC boosted its holdings in Inovio Pharmaceuticals by 46.5% in the 2nd quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 11,554 shares during the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Trading Down 3.0%

NASDAQ INO opened at $0.87 on Tuesday. The stock has a market capitalization of $89.94 million, a price-to-earnings ratio of -0.96 and a beta of 1.61. Inovio Pharmaceuticals has a twelve month low of $0.56 and a twelve month high of $2.72. The stock has a 50-day moving average of $1.17 and a 200 day moving average of $1.28.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. Equities analysts predict that Inovio Pharmaceuticals will post -0.72 EPS for the current fiscal year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells.

Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.